Non-alcoholic fatty liver disease severity, central fat mass and adinopectin: A close relationship

Clujul Medical

Volumn 88, Issue 4, 2015, Pages 489-493

  Abenavoli, Ludovico ^a,b   Di Renzo, Laura ^b   Guzzi, Pietro Hiram ^a   Pellicano, Rinaldo ^c   Milic, Natasa ^d   De Lorenzo, Antonino ^b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

^d UNIVERSITY OF NOVI SAD   (Serbia)

Author keywords

Adiponectin; Body composition; Central obesity; Insulin resistance; Non alcoholic fatty liver disease

Indexed keywords

EID: 84958950166     PISSN: 12222119     EISSN: 20668872     Source Type: Journal    
DOI: 10.15386/cjmed-595     Document Type: Article

References (21)

1. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28:155-161.
2. Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol. 2013;59:859-871.
3. Garinis GA, Fruci B, Mazza A, De Siena M, Abenavoli S, Gulletta E, et al. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes (Lond). 2010;34:1255-1264.
4. Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007;102:2708-2715.
5. Abenavoli L, Greco M, Nazionale I, Peta V, Milic N, Accattato F, et al. Effects of Mediterranean diet supplemented with silybin-vitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9(4):519-527.
6. Canale MP, Manca di Villahermosa S, Martino G, Rovella V, Noce A, De Lorenzo A, et al. Obesity-related metabolic syndrome: mechanisms of sympathetic overactivity. Int J Endocrinol. 2013;2013:865965. doi: 10.1155/2013/865965.
7. De Lorenzo A, Del Gobbo V, Premrov MG, Bigioni M, Galvano F, Di Renzo L. Normal-weight obese syndrome: early inflammation? Am J Clin Nutr. 2007;85:40-45.
8. Andreoli A, Scalzo G, Masala S, Tarantino U, Guglielmi G. Body composition assessment by dual-energy X-ray absorptiometry (DXA). Radiol Med. 2009;114:286-300.
9. Bazzocchi A, Diano D, Ponti F, Salizzoni E, Albisinni U, Marchesini G, et al. A 360-degree overview of body composition in healthy people: relationships among anthropometry, ultrasonography, and dual-energy x-ray absorptiometry. Nutrition. 2014;30:696-701.
10. Mraz M, Haluzik M. The role of adipose tissue immune cells in obesity and low-grade inflammation. J Endocrinol. 2014;222:R113-R127.
11. Abenavoli L, Luigiano C, Guzzi PH, Milic N, Morace C, Stelitano L, et al. Serum adipokine levels in overweight patients and their relationship with non-alcoholic fatty liver disease. Panminerva Med. 2014;56:189-193.
12. Abenavoli L, Peta V. Role of adipokines and cytokines in non-alcoholic fatty liver disease. Rev Recent Clin Trials. 2014;9(3):134-140.
13. Williams DP, Going SB, Milliken LA, Hall MC, Lohman TG. Practical techniques for assessing body composition in middle-aged and older adults. Med Sci Sports Exerc. 1995;27:776-783.
14. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care. 2003;26:3320-3325.
15. Cervelli V, Di Renzo L, Grimaldi M, Di Fede MC, Gentile P, Gravante G, et al. Dual energy X-ray absorptiometry in pre-obese/obese women undergoing reduction mammaplasty. J Plast Reconstr Aesthet Surg. 2009;62:e187-e189.
16. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
17. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330-344.
18. Asrih M, Jornayvaz FR. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. J Endocrinol. 2013;218:R25-R36.
19. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. 1999. Biochem Biophys Res Commun. 2012;425:560-564.
20. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism. 2011;60:313-326.
21. Christou GA, Tellis KC, Elisaf MC, Tselepis AD, Kiortsis DN. High density lipoprotein is positively correlated with the changes in circulating total adiponectin and high molecular weight adiponectin during dietary and fenofibrate treatment. Hormones (Athens). 2012;11:178-188.